Neuroprotective potential of 17-oximino-16-arylidene steroids: In vivo and in silico investigations.

IF 4.2 3区 医学 Q1 PHARMACOLOGY & PHARMACY
Ranjit Singh, Prerna, Ranju Bansal
{"title":"Neuroprotective potential of 17-oximino-16-arylidene steroids: In vivo and in silico investigations.","authors":"Ranjit Singh, Prerna, Ranju Bansal","doi":"10.1016/j.ejphar.2025.177467","DOIUrl":null,"url":null,"abstract":"<p><p>Several recent literature reports indicate the strong neuroprotective potential of synthetic heterosteroids, still search for potent, safer and effective neuroprotective steroidal molecules continues. In the current study, a new series of 17-oximino-16-substituted steroids (1-8) has been evaluated in MPTP-induced Parkinson's disease in mice and amyloid-β induced Alzheimer's disease in rats with an intention to discover an effective and efficient neuroprotective molecule. Behavioural studies followed by histopathological and estimation of the several neuroinflammatory biochemical parameters such as acetylcholinesterase, lipid peroxide, reactive oxygen, and nitric oxide species were carried out. A significant improvement in cognitive and locomotive dysfunctions was observed after treatment with these compounds. In silico molecular docking and simulation studies also correlated with the neuroprotective effects of the steroidal oximes 1-8 as strong binding affinities for TNF-α, IL-1β, AChE and β-secretase were seen. Among all the compounds, 4-pyridylidene (3) and 2-pyridylidene (1) substituted steroids displayed maximum neuroprotective efficacy in animal models of Parkinson's disease and Alzheimer's disease, respectively, and produced effects better than standard drugs. Hence, a new series of 16-arylideno-17-oximino steroids has been identified as potent neuroprotective agents which could be further explored structurally and clinically to discover and develop lead drug molecules useful for the treatment of Parkinson's and Alzheimer's disease.</p>","PeriodicalId":12004,"journal":{"name":"European journal of pharmacology","volume":" ","pages":"177467"},"PeriodicalIF":4.2000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejphar.2025.177467","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Several recent literature reports indicate the strong neuroprotective potential of synthetic heterosteroids, still search for potent, safer and effective neuroprotective steroidal molecules continues. In the current study, a new series of 17-oximino-16-substituted steroids (1-8) has been evaluated in MPTP-induced Parkinson's disease in mice and amyloid-β induced Alzheimer's disease in rats with an intention to discover an effective and efficient neuroprotective molecule. Behavioural studies followed by histopathological and estimation of the several neuroinflammatory biochemical parameters such as acetylcholinesterase, lipid peroxide, reactive oxygen, and nitric oxide species were carried out. A significant improvement in cognitive and locomotive dysfunctions was observed after treatment with these compounds. In silico molecular docking and simulation studies also correlated with the neuroprotective effects of the steroidal oximes 1-8 as strong binding affinities for TNF-α, IL-1β, AChE and β-secretase were seen. Among all the compounds, 4-pyridylidene (3) and 2-pyridylidene (1) substituted steroids displayed maximum neuroprotective efficacy in animal models of Parkinson's disease and Alzheimer's disease, respectively, and produced effects better than standard drugs. Hence, a new series of 16-arylideno-17-oximino steroids has been identified as potent neuroprotective agents which could be further explored structurally and clinically to discover and develop lead drug molecules useful for the treatment of Parkinson's and Alzheimer's disease.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.00
自引率
0.00%
发文量
572
审稿时长
34 days
期刊介绍: The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems. The scope includes: Behavioural pharmacology Neuropharmacology and analgesia Cardiovascular pharmacology Pulmonary, gastrointestinal and urogenital pharmacology Endocrine pharmacology Immunopharmacology and inflammation Molecular and cellular pharmacology Regenerative pharmacology Biologicals and biotherapeutics Translational pharmacology Nutriceutical pharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信